Trial Profile
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Cervical Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 19 Jul 2019 Status changed from recruiting to completed.
- 13 Jul 2011 New trial record